Immunogenicity of In Vitro-Transcribed RNA
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Conspectus In vitro -transcribed RNAs are emerging as new biologics for therapeutic innovation, as exemplified by their application recently in SARS-CoV-2 vaccinations. RNAs prepared by in vitro transcription (IVT) allow transient expression of proteins of interest, conferring safety over DNA- or virus-mediated gene delivery systems. However, in vitro -transcribed RNAs should be used with caution because of their immunogenicity, which is in part triggered by double-stranded RNA (dsRNA) byproducts during IVT. Cellular innate immune response to dsRNA byproducts can lead to undesirable consequences, including suppression of protein synthesis and cell death, which in turn can detrimentally impact the efficacy of mRNA therapy. Thus, it is critical to understand the nature of IVT byproducts and the mechanisms by which they trigger innate immune responses. Our lab has been investigating the mechanisms by which the innate immune system discriminates between “self” and “nonself” RNA, with the focus on the cytoplasmic dsRNA receptors retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated 5 (MDA5). We have biochemically and structurally characterized critical events involving RNA discrimination and signal transduction by RIG-I or MDA5. We have used in vitro -transcribed RNAs as tools to investigate RNA specificity of RIG-I and MDA5, which required optimization of the IVT reaction and purification processes to eliminate the effect of IVT byproducts. In this Account, we summarize our current understanding of RIG-I and MDA5 and IVT reactions and propose future directions for improving IVT as a method to generate both research tools and therapeutics. Other critical proteins in cellular innate immune response to dsRNAs are also discussed. We arrange the contents in the following order: (i) innate immunity sensors for nonself RNA, including the RIG-I-like receptors (RLRs) in the cytosol and the toll-like receptors (TLRs) in the endosome, as well as cytoplasmic dsRNA-responding proteins, including protein kinase R (PKR) and 2′,5′-oligoadenylate synthetases (OASes), illustrating the feature of protein–RNA binding and its consequences; (ii) the immunogenicity of IVT byproducts, specifically the generation of dsRNA molecules during IVT; and (iii) methods to reduce IVT RNA immunogenicity, including optimizations of RNA polymerases, reagents, and experimental conditions during IVT and subsequent purification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to human moDCs (Figure 1c), T_WT-produced mRNAs yielded lower expression of the encoded fluorescent protein, likely due to dsRNA-mediated activation of PKR or OASes, which inhibit protein synthesis.42”
From Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses (2024) · cites this paper as [42]
In the citing paper
“To prevent their formation, some studies reported that the use of the modified nucleobase m1Ψ reduces T7 RNAP efficiency and the production of antisense–sense dsRNA.41,42”
From Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses (2024) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791 · cited 1×
“11,12 Aberrant activation elicited by, for example, mutations in critical genes results in inflammation and immune diseases.”
BackgroundDNA methylation and its basic function
Moore, L. D., Le, T., & Fan, G. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.112 · Cited by 4,906 · cited 1×
“70 Similarly, mammalian RNAs, including mRNAs, are modified post-transcriptionally.”
BackgroundSpecies-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947 · cited 1×
“39 The immunogenicity of U-rich stretches was demonstrated using mouse and human cells in a study showing that uridine stretches are strong ligands for TLR7.”
BackgroundKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · cited 2×
“42 Extensive efforts have been made to investigate the protective role of modified nucleosides toward in vitro-transcribed mRNAs.”
BackgroundmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160 · cited 1×
“56 OAS3 is more potent in responding to dsRNAs than OAS1 and OAS2 and is the primary activator of RNase L. 57 In vitro-transcribed RNAs activate the OAS–RNase L pathway and inhibit their own translation.”
BackgroundKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · cited 4×
“43,74,75 These chemically modified nucleotides containing in vitro-transcribed RNAs may lose efficient binding affinity to innate immune receptors.”
BackgroundInfluentialImmune Signaling by RIG-I-like Receptors
Loo, Y.-M., & Gale, M. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.003 · Cited by 1,875 · cited 1×
“16,17 They have similar amino acid sequences and domain architectures, with two tandem N-terminal caspase activation and recruitment domain (CARD) motifs, a central DExD/H box helicase domain, and a C-terminal domain (CTD) (Figure 1a).”
BackgroundmRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062 · cited 1×
“41–43”
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898 · cited 3×
“82 85 High-performance liquid chromatography (HPLC) was reported to effectively remove dsRNA contaminants; however, the resultant in vitro-transcribed mRNA, composed of unmodified nucleotides, remained immunostimulatory—DCs maintained high levels of TNF-α and IFN-α .”
BackgroundExpression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733 · cited 4×
“43 Studies have shown that for IVT mRNA, translation efficacy is higher with modified nucleotides than with normal nucleotides.”
BackgroundInfluentialStructural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA
Liu, L., Botos, I., Wang, Y., Leonard, J. N., Shiloach, J., Segal, D. M., & Davies, D. R. (2008) · Science · doi:10.1126/science.1155406 · Cited by 733
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701 · cited 3×
“72,73 Consistently, in mice, modified nucleosides such as s2U/m5C, ψ /m5C, and ψ reduce the immunogenicity of in vitro-transcribed mRNA.”
BackgroundIncorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682 · cited 2×
“49,50 2 ′ ,5 ′ -Oligoadenylate synthetase (OAS) binds to dsRNA to produce 2 ′ ,5 ′ -oligoadenylate (2–5A), which serves as a secondary messenger to activate RNase L by inducing its dimerization or oligomerization.”
BackgroundA facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
Zhang, Z., Ohto, U., Shibata, T., Krayukhina, E., Taoka, M., Yamauchi, Y., Tanji, H., Isobe, T., Uchiyama, S., Miyake, K., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.011 · Cited by 461
Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated Inflammation
Ahmad, S., Mu, X., Yang, F., Greenwald, E., Park, J. W., Jacob, E., Zhang, C.-Z., & Hur, S. (2018) · Cell · doi:10.1016/j.cell.2017.12.016 · Cited by 449 · cited 1×
“The gain-of-function mutations of MDA5 showed more IFN-activating capacity at the cost of self-recognition, 3 leading to the onset of autoimmune diseases.”
BackgroundSelf-citationDouble-Stranded RNA Sensors and Modulators in Innate Immunity
Hur, S. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041356 · Cited by 420 · cited 2×
“16,17 They have similar amino acid sequences and domain architectures, with two tandem N-terminal caspase activation and recruitment domain (CARD) motifs, a central DExD/H box helicase domain, and a C-terminal domain (CTD) (Figure 1a).”
BackgroundSelf-citationToll-like receptor 8 senses degradation products of single-stranded RNA
Tanji, H., Ohto, U., Shibata, T., Taoka, M., Yamauchi, Y., Isobe, T., Miyake, K., & Shimizu, T. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2943 · Cited by 404 · cited 2×
“33,34 Once bound to their ligands, TLR7 and TLR8 recruit the downstream adaptor myeloid differentiation primary response 88 (MyD88), which in turn associates with interleukin-1 receptor-associated kinase 4 (IRAK4) and IRAK1/IRAK2 to form the Myddosome.”
BackgroundSrivastava, S. P., Kumar, K. U., & Kaufman, R. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.2416 · Cited by 378 · cited 1×
“45,46 Similar to RLRs, PKR binds to dsRNA in a sequence-independent manner.”
BackgroundTailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376 · cited 1×
“9 Although these modifications improve the stability and translational efficiency of in vitro-transcribed RNAs, they are challenged by the host innate immune system, which recognizes nonself molecules frequently found in invading pathogens or under pathological conditions.”
BackgroundAnderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr586 · Cited by 356 · cited 2×
“58 A schematic view of cellular innate immunity is shown in Figure 3.”
BackgroundImpact of mRNA chemistry and manufacturing process on innate immune activation
Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354 · cited 2×
“86 Thus, using a combination of modified nucleotides for IVT and HPLC purification can produce non-immunostimulatory mRNAs.”
BackgroundMethodPardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · cited 1×
“58 80 However, it should be noted that exactly why certain modifications are more effective than others in evading translational suppression is unclear.”
BackgroundActivation of RNase L is dependent on OAS3 expression during infection with diverse human viruses
Li, Y., Banerjee, S., Wang, Y., Goldstein, S. A., Dong, B., Gaughan, C., Silverman, R. H., & Weiss, S. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519657113 · Cited by 285 · cited 1×
“56 OAS3 is more potent in responding to dsRNAs than OAS1 and OAS2 and is the primary activator of RNase L. 57 In vitro-transcribed RNAs activate the OAS–RNase L pathway and inhibit their own translation.”
BackgroundKarikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282
Svitkin, Y. V., Cheng, Y. M., Chakraborty, T., Presnyak, V., John, M., & Sonenberg, N. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx135 · Cited by 278 · cited 1×
“49,50,77 Moreover, replacement of U with ψ protects the RNA molecule from activating OAS and the downstream RNase L-mediated RNA cleavage event.”
BackgroundVaidyanathan, S., Azizian, K. T., Haque, A. K. M. A., Henderson, J. M., Hendel, A., Shore, S., Antony, J. S., Hogrefe, R. I., Kormann, M. S. D., Porteus, M. H., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.010 · Cited by 262 · cited 1×
“4 Other studies have shown that using uridine-depleted sequences lowers the immunogenicity of in vitro-transcribed Cas9 mRNA containing modified nucleosides by an unknown mechanism, 81 supporting the notion that TLR7 and TLR8 bind U-containing ssRNAs.”
BackgroundDurbin, A. F., Wang, C., Marcotrigiano, J., & Gehrke, L. (2016) · mBio · doi:10.1128/mbio.00833-16 · Cited by 238
An origin of the immunogenicity of in vitro transcribed RNA
Mu, X., Greenwald, E., Ahmad, S., & Hur, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky177 · Cited by 218 · cited 2×
“4,78 We speculate that modified nucleotides may benefit IVT by increasing transcript purity and decreasing transcript immunogenicity.”
BackgroundSelf-citationGil, J., Alcamí, J., & Esteban, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4653 · Cited by 199 · cited 1×
“45,46 Similar to RLRs, PKR binds to dsRNA in a sequence-independent manner.”
BackgroundEdwards, D. K., Jasny, E., Yoon, H., Horscroft, N., Schanen, B., Geter, T., Fotin-Mleczek, M., Petsch, B., & Wittman, V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1111-6 · Cited by 186
HPLC purification of in vitro transcribed long RNA
Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_3 · Cited by 180
De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.161 · Cited by 122
Analysis of High-Affinity Binding of Protein Kinase R to Double-Stranded RNA
Husain, B., Mukerji, I., & Cole, J. L. (2012) · Biochemistry · doi:10.1021/bi301226h · Cited by 51
Cited by
Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery
Suzuki, Y., Yakuwa, M., Sato, M., Samaridou, E., Beck-Broichsitter, M., Maeki, M., Tokeshi, M., Yamada, Y., Harashima, H., & Sato, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113687 · Cited by 37
RNA stability enhancers for durable base-modified mRNA therapeutics
Jung, S.-J., Seo, J. J., Lee, S., Hyun, S.-I., Lee, J.-E., Lee, S., Lee, Y., Chang, H., Lee, H., Kim, J.-H., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02891-7 · Cited by 26
Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses
Camperi, J., Roper, B., Freund, E., Leylek, R., Nissenbaum, A., Galan, C., Caothien, R., Hu, Z., Ko, P., Lee, A., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c04162 · Cited by 22
Jo, S., Lee, J., Park, S.-I., Kim, Y., Yoon, S., Lee, S., Cho, S., Cho, Y., Oh, A., Ha, D., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114471 · Cited by 14
Selection of UTRs in mRNA-Based Gene Therapy and Vaccines
Volkhin, I. A., Paremskaia, A. I., Dashian, M. A., Smeshnova, D. S., Pavlov, R. E., Mityaeva, O. N., Volchkov, P. Y., & Deviatkin, A. A. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297924604659 · Cited by 7
Metadata
- Authors
- Mu, X., & Hur, S.
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-10-22
- Volume
- 54
- Issue
- 21
- Pages
- 4012-4023
- ISSN
- 0001-4842 (ISSN-L)
- 1520-4898
- OpenAlex
- W3207060908
- Cited by
- 134
- References
- 35
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.